A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

Prithviraj BoseDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Mahesh SwaminathanDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Naveen PemmarajuDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Alessandra FerrajoliDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Elias J. JabbourDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Naval G. DaverDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Courtney D. DiNardoDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Yesid AlvaradoDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Musa YilmazDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Julie Huynh-LuDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Wei QiaoDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Xuemei WangDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Aurelio MatamorosDivision of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information

Lingsha ZhouDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Sherry PierceDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Kurt D. SchroederDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Hagop M. KantarjianDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Srdan VerstovsekDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Correspondence[email protected]

Articles from other publishers (14)